Immunocore Working With EMA On Novel TCR Therapy Filing

While Immunocore is not giving details of what issues it still needs to address regarding its EU filing for tebentafusp, it said the drug is continuing to undergo an accelerated assessment by the CHMP. 

Cytotoxic T cells search and destroy mutated cancer cells - 3d illustration
Tebentafusp redirects T-cells to kill tumor cells • Source: Alamy

Immunocore says it is continuing to work closely with the European Medicines Agency on the marketing application for its novel T-cell receptor (TCR) therapy, tebentafusp, after the agency held fire on adopting an opinion on whether the drug should receive EU-wide approval.

Tebentafusp, intended for treating the rare and aggressive cancer of the eye, metastatic uveal melanoma, continues to be reviewed on...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>